Sanofi rakes in $2.25B in bond sale; Hungarian regulators crack down on alleged drug cartel;

@FiercePharma: Regulatory challenges top of mind at inaugural ACI animal health forum. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. Story | Follow @CarlyHFierce

> Sanofi ($SNY) raised €2 billion ($2.25 billion) in a bond sale to fund operations and pay down existing debt. Release

> Hungarian regulators fined three drug companies 792.2 million forints ($2.87 million) each for acting as a cartel on a public tender by the Budapest Healthcare Centre. Story

> Some doctors are cautioning against using Sprout Pharmaceuticals' controversial female libido drug, Addyi. Article

> Bayer appointed Natalie Bartner, Sanofi's former VP head of commercial strategy, as president of its North America consumer care unit. Story

> A new report funded by Bristol-Myers Squibb ($BMY) shows that cancer deaths in the U.K. cost the country more than half a billion pounds a year. Article

Medical Device News

@FierceMedDev: Study: close management of blood pressure reduces cardiac disease, deaths. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED: FDA begs manufacturers to participate in global single audit pilot, says next stage may not be voluntary. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Advera Health Analytics: Merck statins linked to more muscle side effects than rest of class. Report | Follow @EmilyWFierce

> Olympus, Sony focus on JV with high-def endoscope launch. Report

> Med tech IPOs fall into place: Penumbra, Symetis, Novocure and Adesto. Story

> Philips, Salesforce develop diabetes app, system to marry consumer and medical data. Article

Biotech News

@FierceBiotech: Patrick Soon-Shiong plucks another cancer drug out of Amgen's pipeline. Story | Follow @FierceBiotech

@JohnCFierce: Lipstick on a pig: XenoPort plunges as investors sour fast on "positive" psoriasis data. Article | Follow @JohnCFierce

@DamianFierce: Reminder that $NVO is risking billions of dollars on Tresiba data that management ~hasn't actually seen~. More from Reuters | Follow @DamianFierce

> Amicus plots an end-of-year FDA filing for its resuscitated lead drug. Report

> Celgene antes up $25M for first seat at antibody engineers' new deal table. Story

> GW sees a future in schizophrenia with its cannabis-based pipeline. Article

Drug Delivery News

> Novo, MIT's Langer Lab announce research alliance aimed at creating novel drug delivery devices. More

> Gene delivery player to go public this week, aiming to raise $100M. Item

> U.S.-Irish collaboration picks up $4.4M in pursuit of pancreatic cancer nanomeds. Report

> New surface protein found on cancer cells offers specific drug targeting, could spare fertility. Story

> Study finds ultrasound contrast agents can improve delivery of chemotherapy drugs. Article

Pharma Manufacturing News

> Abbott run-in with Indian regulators illustrates India's shortcomings: Reuters. More

> Endo's Qualitest recalls blood pressure, gout drugs. News

> California law requires drug info in 6 languages. Item

> U.K.'s Abzena shells out $8.4M for San Diego-based CDMO. Story

> FDA bans India's Polydrug plant, following actions by EMA and Canada. Article

Pharma Asia News

> China plans public health push on cancer, wants to expand screening. Report

> Japan's Eisai to present papers on Lenvima clinical data at European Cancer Congress. More

> Takeda crosses Actos settlement threshold as 96% of plaintiffs seek resolution. Story

> China plans medical exchange league with Arab states. Item

> Indian generics bid to challenge Gilead's Sovaldi patent dropped. Article

And Finally… A panel of U.S. medical experts is recommending daily low-dose aspirin for adults between ages 50 and 59 who have increased risk of heart disease and stroke. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.